TLR9 and B-cell non-Hodgkin lymphoma: They demonstrate that combination of the TLR9 agonist (CpG) with the STAT3 decoy inhibitor into a single oligodeoxynucleotide conjugate generates two-pronged therapeutic effect by direct and T cell-mediated antitumor effects against B cell lymphoma cells in vivo.